Institut Rosell-Lallemand Enriches its Probiotic Portfolio with the Acquisition of LAFTI Business from DSM Food Specialties

DSM Food Specialties retains the dairy portion of LAFTI business through a licence agreement, reflecting the company’s strategy to concentrate on food and beverage probiotic applications.

8 Mar 2010 --- Institut Rosell-Lallemand announces completion of the acquisition of LAFTI for dietary supplements business from DSM. LAFTI is a recognised range of probiotic strains with targeted health benefits, supported by strong scientific and clinical evidence. For Institut Rosell-Lallemand, LAFTI represents an excellent asset to its existing portfolio of quality probiotics targeting specific health segments such as gut health, immunology, women’s and children’s health. DSM Food Specialties retains the dairy portion of LAFTI business through a licence agreement, reflecting the company’s strategy to concentrate on food and beverage probiotic applications.

LAFTI probiotic strains have been developed and documented by DSM as a result of an extensive scientific research program. Their documented benefits cover different areas of immunity, healthy digestion and vitality level. They have been marketed for 6 years around the world, in both dietary supplements and dairy applications, with excellent track-record of safety, efficacy and recognition from key scientific experts. They have excellent safety, stability and survival properties, enabling optimal delivery of active probiotics to the gut, their site of action. LAFTI probiotics are suitable for a range of dietary supplement formats, such as hard gel capsules, tablets or soft gels. Their high concentration and excellent survival and stability properties enable a variety of formulations: alone or in associated with prebiotics, minerals, vitamin, or other healthy ingredients.

Olivier Clech, Vice President for Lallemand Human and Animal Nutrition comments : “DSM LAFTI range of probiotic strains benefits from an excellent reputation and is endorsed by strong scientific and clinical back-up. Over the years, DSM has developed major partnerships with key players of the health and food industry as well as recognized scientific opinion leaders. The quality and reputation of these strains fits perfectly in our own probiotic portfolio, complementing it with new species, such as Bifidobacterium animalis lactis and offering novel areas of applications such as sport health and athletes recovery.”

LAFTI range of documented probiotics comprises of three strains:

* Lactobacillus acidophilus LAFTI L10 (L10)
* Lactobacillus casei LAFTI L26 (L26)
* Bifidobacterium animalis lactis LAFTI B94 (B94).

LAFTI L10 is a probiotic of dairy origin, documented for its apparent immune enhancing properties,. L10 has shown in a human trial on 285 subjects benefits in reducing cold and flu symptoms and reduced use of medication. Another study showed that L10 apparently restores suppressed immune functions in fatigued athletes as evidenced by biomarkers.

There is a patent pending for the application of the LAFTI strains in the reduction of the impact of winter infections in healthy adults.

Lallemand and DSM Food Specialties are committed to making the transition as smooth and simple as possible. Lallemand is committed to providing customers the same excellent service and support that they have come to expect with LAFTI.